Fidelity Investments’s ImmuCell ICCC Stock Holding History

Fidelity Investments’s Portfolio ICCC Stock Details ICCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1	Closed	-$5	–	5488
2023 Q1	$5	Buy	+1	New	+$6	﹤0.01%	5215

Other funds holding ICCC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SRC

Shufro Rose & Co New York $1.47B AUM 19.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EFMC

Empire Financial Management Company New York $442M AUM 24.42% 1-Year Est. Return

OMC

Overbrook Management Corp New York $663M AUM 35.04% 1-Year Est. Return

Fidelity Investments's ICCC Position: Q2 2023 in Review

Fidelity Investments sold out of ImmuCell (ICCC) in Q2 2023, closing a stake of 1 share — an estimated $5 sold.

Fidelity Investments first reported a position in ICCC in Q1 2023 and held it in 1 quarter. The position peaked at $5 in Q1 2023. 31 funds tracked by Wall St. Rank hold ICCC as of Q2 2023.

Fidelity Investments reported no remaining ImmuCell position as of Q2 2023 after selling out during the quarter.
Fidelity Investments sold 1 ImmuCell share in Q2 2023, an estimated $5.
Fidelity Investments first reported a position in ImmuCell in Q1 2023 and held it in 1 quarter.
Fidelity Investments's ImmuCell position peaked at $5 in Q1 2023.
31 funds tracked by Wall St. Rank held ImmuCell as of Q2 2023.

Based on Fidelity Investments's 13F filing for Q2 2023, filed 11 Aug 2023.